Exalenz Bioscience


Therapeutic Area(s):
Gastrointestinal, General Health, Primary Care
Company Status:
Revenue Growth

Company at a Glance

Exalenz Bioscience Ltd. develops and commercializes advanced systems that extract vital information for diagnostics from subtle changes in the patient’s exhaled breath based on its BreathID™ technology platform.
These products improve the quality of patient care, enhance clinic and medical center efficiencies and fuel revenue generation. Our proprietary core technology enables medical specialists to identify and manage specific digestive and liver conditions with unprecedented ease, patient comfort, and clinical precision.
The company’s flagship BreathID™ Hp is an extremely accurate, easy-to-use, self-calibrating urea breath test (UBT) and the emerging gold standard to diagnose, monitor and manage gastric H. pylori bacteria infection. It is estimated that over 50% of the world’s population is infected with H. pylori. Recent studies estimate that more than 90% of duodenal ulcers and 80% of gastric complications are caused by H. pylori, conditions which can ultimately lead to stomach cancer and other gastric complications if left untreated.
The design of sophisticated diagnostic systems that are simple to operate is a hallmark of Exalenz Bioscience.
The company conducts ongoing research in collaboration with leading clinical and industrial partners in the U.S., Europe, Asia, and Israel. Exalenz Bioscience aims to become a leading provider of accurate, breath test-based, point-of-care disease management solutions for a broad range of GI and liver disorders.

Technology & Product(s)

The BreathID® technology platform answers the long-standing need for fast, convenient and accurate monitoring of functional diseases of the liver and gastrointestinal tract. It measures parts-per-million changes in the molecular 13C/12C ratio of the patient’s exhaled breath – continuously, automatically and in real time.
The real-time analysis is powered by the BreathID technology platform, which incorporates a number of proprietary core technologies, such as MCS™ (Molecular Correlation Spectroscopy), and online analysis algorithms.
BreathID products are designed for ease of use and user-friendly operation. Testing can be performed in the office or clinic.
The BreathID® Hp is the most innovative next generation Urea Breath Test (UBT) for diagnosing H. pylori infection and for post-treatment monitoring of H. pylori infection in adults. Its technology is based on measuring the parts-per-million changes in the molecular 13C/12C ratio of the patient’s exhaled breath. This is measured before and after the ingestion of a low dosage of 13C labeled urea dissolved in water. The test is non-radioactive and completely safe. Within 10-15 minutes the real-time analysis is complete and results are available immediately. These results can easily be uploaded into the patient’s EMR.

Goals

Objectives: Locate distributors.
Target businesses: Medical device distribution.
Target Countries: Australia, Austria, Baltics, Bulgaria, Canada, China, Czech Republic, France, Germany, Holland, Hungary, India, Poland, Romania, Russia, S. Africa, S. Korea, Singapore, Slovakia, Spain, Sweden, Switzerland, Ukraine.